×
About 568,340 results

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/dr-usmani-on-activity-of-teclistamab-in-relapsed-refractory-multiple-myeloma

May 30th, 2020

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/view/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
https://www.nature.com/articles/s41577-020-0389-z

T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, the source and clinical relevance of the reactivity remains unknown. It is speculated that this reflects T cell memory to circulating ‘common cold’ coronaviruses. It will be important to define specificities of these T cells and assess their association with COVID-19 disease severity and vaccine responses.

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
https://www.nature.com/articles/s41586-020-2598-9_reference.pdf
Nature

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic1,2 . Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms determining such variable outcomes remain unresolved. Here, we investigated SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cel...

Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients
https://www.biorxiv.org/content/10.1101/2020.03.25.009084v2.full

Recent reports suggest an association between COVID-19 and altered olfactory function. Here we analyze bulk and single cell RNA-Seq datasets to identify cell types in the olfactory epithelium that express molecules that mediate infection by SARS-CoV-2 (CoV-2), the causal agent in COVID-19. We find in both mouse and human datasets that olfactory sensory neurons do not express two key genes invol...

HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
https://ascopost.com/news/may-2020/hif2a-inhibitor-for-von-hippel-lindau-disease-associated-renal-cell-carcinoma/

May 29th, 2020 - In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC).

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
https://ascopost.com/videos/asco20-virtual-scientific-program/shaji-kumar-on-carfilzomib-lenalidomide-bortezomib-and-dexamethasone-in-multiple-myeloma/

May 29th, 2020 - Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200193/full/

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200181/full/

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

KarMMa: BCMA-Targeting CAR T Excellent Option for Relapsed/Refractory Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200194/full/

May 28th, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to phase II data from the KarMMa trial (Abstract 8503).

Early Data Show Bispecific Antibody Teclistamab Safe, Active in Relapsed/Refractory Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200175/full/

May 28th, 2020 - Teclistamab, a IgG-4 bispecific antibody targeting BCMA and CD3, appears to be safe in patients with relapsed or refractory multiple myeloma, according to phase I data presented during the ASCO20 Virtual Scientific Program (Abstract 100).

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter study conducted in patients with AML to determine if integrated palliative and oncology care could improve QoL and other important aspects of patient...

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

Pharmacokinetically Guided Dose Optimization of Pazopanib Is Feasible in Daily Practice, Efficacy Not Determined
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200127/full/

May 12th, 2020 - Results from the Dutch Pharmacology Oncology Group (DPOG) therapeutic drug monitoring (TDM) study of pazopanib in patients with renal cell carcinoma (RCC) and soft tissue sarcoma (STS) demonstrated that pharmacokinetically guided dose optimization using cost-neutral interventions can be achieved in daily practice (Abstract 3598).